PCM
CORT icon

Penserra Capital Management’s Corcept Therapeutics CORT Stock Holding History

Penserra Capital Management’s Portfolio CORT Stock Details CORT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-3,017
Closed -$139K – 1122
2024
Q3 		$139K Buy
+3,017
New +$107K ﹤0.01% 747
2017
Q4 		– Sell
-21,624
Closed -$417K – 419
2017
Q3 		$417K Buy
+21,624
New +$322K 0.1% 105

Other funds holding CORT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ISL
Ingalls & Snyder LLC New York $3.66B AUM 57.76% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $6.56B AUM 32.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return

Penserra Capital Management's CORT Position: Q4 2024 in Review

Penserra Capital Management sold out of Corcept Therapeutics (CORT) in Q4 2024, closing a stake of 3,017 shares — an estimated $139K sold.

Penserra Capital Management first reported a position in CORT in Q3 2017 and held it in 2 quarters. The position peaked at $417K in Q3 2017. 367 funds tracked by Wall St. Rank hold CORT as of Q4 2024.

  • Penserra Capital Management reported no remaining Corcept Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Penserra Capital Management sold 3,017 Corcept Therapeutics shares in Q4 2024, an estimated $139K.
  • Penserra Capital Management first reported a position in Corcept Therapeutics in Q3 2017 and held it in 2 quarters.
  • Penserra Capital Management's Corcept Therapeutics position peaked at $417K in Q3 2017.
  • 367 funds tracked by Wall St. Rank held Corcept Therapeutics as of Q4 2024.

Based on Penserra Capital Management's 13F filing for Q4 2024, filed 13 Feb 2025.